ArticleFrontiers in immunology2025
Deficiency of HMGN2 enhances antibacterial activity of macrophages by promoting H3 histone modification-mediated CD14/iNOS expression.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-mobility group nucleosomal-binding domain 2 (HMGN2) is a widely recognized chromatin-structural protein within the nucleus of eukaryotes. It has been demonstrated to be implicated in immune responses during bacterial infection. Nevertheless, the regulatory mechanism of HMGN2 in the antibacterial process of macrophages remains unclear. In this research, distinct alterations in HMGN2 expression in macrophages were observed subsequent to microbial stimulation. To investigate the role of HMGN2 in macrophages during infection, the CRISPR-Cas9 technology was employed to construct an HMGN2-knockout RAW264.7 cell line. It was verified that HMGN2 knockout could significantly enhance the bactericidal and phagocytic capabilities of macrophages. The mechanistic investigation revealed that cluster of differentiation 14 (CD14) was transcriptionally promoted in HMGN2-knockout macrophages. HMGN2 knockout regulates CD14 expression by augmenting histone epigenetic modification levels on the CD14 gene promoter, including H3K4me3, H3K9ac, and H3K27ac. Moreover, HMGN2 knockout can activate the CD14-mediated mitogen-activated protein kinase (MAPK) signaling pathways to facilitate nitric oxide (NO) production. This study uncovers a crucial role of HMGN2 in the macrophage-mediated host immune response. HMGN2 is anticipated to serve as a therapeutic target for the treatment of infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.